



May 24, 2019

Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes.
In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Company name: RIBOMIC Inc.
Representative: Yoshikazu Nakamura, President and CEO
Stock code: 4591
Listing: Tokyo Stock Exchange, Mothers Market
Contact: Shoji Yonebayashi, Corporate Officer,
Corporate Planning Department

**Announcement of the Patent Application regarding RBM-001 licensed to Otsuka
Pharmaceuticals and Memorandum of Understanding with Otsuka Pharmaceuticals
Regarding Use of Research Results for RBM-001**

RIBOMIC Inc. submitted a patent application today regarding RBM-001, as a drug for the treatment of diseases involving abnormal bone growth and bone metabolism, the compound that was licensed to Otsuka Pharmaceuticals Co., Ltd., (“Otsuka”). Joint research based on the agreement with Otsuka of January 1, 2008 revealed that RBM-001 and other nucleic acids have a specific effect on cells that play a role in bone metabolism and the patent application for the invention was filed after getting the results of research and development activities performed in accordance with the licensing agreement with Otsuka of May 8, 2017.

In addition, RIBOMIC and Otsuka have agreed to terminate the licensing agreement and signed a memorandum of understanding for the commercialization of RBM-001 by RIBOMIC, including the payment of royalties to Otsuka. RIBOMIC is going to look for partners for the commercialization of RBM-001 worldwide.

There are expectations that RBM-001 and other nucleic acids may be effective to treat osteosclerosis and other bone disorders, which are rare disease.

There are several types of osteosclerosis and other bone disorders. One is fibrodysplasia ossificans progressiva, in which muscle tissue, tendon tissue and ligament are gradually replaced by bone. Designated an incurable disease, this disorder may start at childhood and can result in death. Another type is ossified posterior longitudinal ligament, an incurable disease where the spine is compressed due to ossification of ligaments, which causes the loss of feeling or movement.

The signing of this memorandum adds RBM-001 to the RIBOMIC pipeline, which also includes RBM-007, a potential treatment for achondroplasia, of candidate drugs for bone diseases. RIBOMIC will make efforts to help the patients suffering from these rare diseases and their families.

This patent application and the memorandum will have no effect on results of operations in this fiscal year or the next few years.